Swiss Medica Inc. ein MUSS
Seite 3 von 4 Neuester Beitrag: 07.11.10 08:44 | ||||
| Eröffnet am: | 26.08.05 13:58 | von: RLDJA | Anzahl Beiträge: | 85 |
| Neuester Beitrag: | 07.11.10 08:44 | von: larsuwe | Leser gesamt: | 18.148 |
| Forum: | Hot-Stocks | Leser heute: | 2 | |
| Bewertet mit: |  | |||
| Seite: < 1 | 2 | | 4 > | ||||
Letter to Shareholders
1/31/06
Dear Shareholders,
When we launched Swiss Medica in June 2003 our goal was to commercialize a family of healthy proprietary bioscience products that relieve chronic ailments that impact all of us and our loved ones. Since then we have launched O24™ Pain Neutralizer, O24 Fibromyalgia™ and PMS Escape® nationally in the United States and Canada.
Our focus has always been to acquire and/or license patented over-the-counter health products that are all-natural, clinically tested and address chronic ailment categories that are currently dominated by prescription drugs. We believe these attributes are
what differentiate us from our competition.
To recap some of our successes over the past 2.5 years:
• Our revenues for fiscal 2005 were US$6.42 million,
compared to approximately US$600,000 in revenues in 2004.
• We have expanded our product distribution to over 21,000 retailers (up from 300 as of December 2003) in Canada and the United States the top drug store retailers in the United States (CVS/Pharmacy and Rite Aid) and all major mass/food/drug store chains in Canada (Shoppers Drug Mart, Loblaws and Wal-Mart Canada to name a few).
• We have clinically tested and have launched in the United States and Canada O24 Fibromyalgia™ as the FIRST focused product for fibromyalgia available in national retailers. Fibromyalgia is a chronic pain ailment that impacts over 10 million Americans. The National Fibromyalgia Association in California has bestowed upon O24 Fibromyalgia™ their official Seal of Approval.
• We acquired the exclusive licensing rights to PMS Escape® the first and only clinically tested and patented over-the- counter dietary supplement for the management of mood, appetite and the ability to concentrate associated with pre- menstrual syndrome, a market that effects up to 27 million women in the Unites States alone. PMS Escape® is now available in retailers in the USA and Canada.
• O24™ Pain Neutralizer has received strong endorsements from recognized leaders in sports (Olympic and professional athletes), medical professionals, and consumer associations (regional arthritis groups in North America, National Fibromyalgia Association).
• O24™ Pain Neutralizer was the third best selling Topical Pain Reliever in Canada in 2005, outselling Ben-Gay, Tiger Balm and Icy Hot (based on dollar sales), according to market research firm ACNielsen Canada.
• Swiss Medica and O24™ Pain Neutralizer were awarded Company of the Year and Product of the Year by the Northern California Arthritis Foundation in 2005.
• In a randomized double blind clinical study conducted in 2005, 88 per cent of the patients who used O24 Fibromyalgia™ reported mild to markedly better improvement from their fibromyalgia pain, versus only 7 per cent who used the placebo. The results of this study were published in Practical Pain Management, a medical journal, in January 2006.
• In addition on February 2, 2006, we announced that the Practical Pain Management Journal, in their January/February 2006 issue, published Dr. Ko’s Randomized Double Blind Clinical Trial on Swiss Medica’s O24 Fibromyalgia™.
Over the next 24-months Swiss Medica has severalmajor goals, including:
• Expand our retail distribution from our current focus on drug store chains to mass market, food and convenience retailers.
• Achieve national distribution of our products in professional channels such as physician offices, pain management clinics, chiropractors and hospital pharmacies.
• Launch Swiss Medica products into international markets outside of the United States and Canada.
• Launch other world class patented, clinically tested safe and effective products for chronic ailments such as depression and cholesterol.
• Build Swiss Medica into a leading consumer healthcare brand focused on elite over-the-counter health products for chronic ailments.
• Create substantial shareholder value.
• Move to a major stock exchange.
Swiss Medica has come a long way since its launch in mid 2003. The coming year is one of great promise and tremendous opportunity. I urge you to visit our websites www.swissmedica.com, www.O24zone.com and
www.pmsescape.com to learn more about our company and products. I am confident that you will join the thousands of people who have used our products to enhance the quality of their lives.
Thank you for your continued support of Swiss Medica.
Raghu Kilambi, CA
CEO
Swiss Medica, Inc.
TORONTO, ONTARIO -- (MARKET WIRE) -- 05/16/06 -- Swiss Medica, Inc. (OTCBB: SWME) to announce that it is launching a television campaign for its PMS Escape product in the Midwest USA beginning this week. The 30-second television spot will air in Columbus, Ohio, Indianapolis, Indiana and Detroit Michigan from May 16 until June 10, 2006 and will highlight PMS Escape as a unique over-the-counter, patented, clinically tested and all-natural product for the mood and appetite symptoms of premenstrual syndrome.
Swiss Medica engaged Spot Runner, a new Internet-based advertising agency located in Los Angeles, Calif., to create the television spot and manage the campaign. Spot Runner specializes in making it fast, easy and affordable for businesses to advertise on TV. The PMS Escape 30 second TV may be viewed at http://www.pmsescape.net/presscenter.html.
The commercial is intended to reach women between the ages of 25 and 45 suffering from the emotional and appetite problems of premenstrual syndrome. "We took a soft approach to reaching our target audience with our first-ever television spot," explains Wendy Kramer, Vice President of Swiss Medica. "We wanted to let women know that we understand how delicate this subject matter is and how important it is to see women like themselves who can conquer the age-old problems of PMS in a natural and healthy way," Kramer continues. "We look forward to great success with our new campaign."
The spot, which highlights how PMS Escape can help women get relief from the anger, irritability and tension of PMS, will be aired during The Today Show, Good Morning America, Ellen and Oprah in the Columbus market, while Indianapolis and Detroit will air the spot on stations such as HGTV, TNT and TBS. "By airing our spots during daytime television shows, we can reach women at a time when they will really listen to what we have to say about PMS Escape," Kramer continues.
PMS Escape is available in the Feminine Hygiene section of CVS/Pharmacy and Meijers and online at Walgreens.com.
Swiss Medica, Inc. (OTCBB: SWME) is pleased to announce that third quarter revenues for the three months ended March 31, 2006, grew 8% over Q1 2005 quarterly results to US$1.22 million.
"While our year-over-year revenues grew, our revenues did decline from Q4 2005." said Chief Executive Officer, Raghu Kilambi. "As we are still in the stage of building brand awareness and gaining distribution, our quarterly revenues will significantly fluctuate. This is due to some quarters yielding significantly larger opening stocking orders for new channels. The good news is that through stringent inventory and cash management, we have decreased our cash outflows from operations in Q1 2006 significantly to (US$399,000) from (US$796,000) in Q4 2005 and (US$2.75 million) in Q1 2005."
Swiss Medica announced many significant achievements in the first 4 months of 2006 including:
- According to sales rankings from ACNielsen, the 30ml spray bottle of O24 Pain Neutralizer was ranked the 3rd best selling product in the topical pain relief category in Canadian drug stores in 2005, based on dollar sales at the retail level. O24 Pain Neutralizer was nationally launched in Canadian drug stores in September 2004.
- O24 Fibromyalgia was able to capitalize on its receipt of the first and only Seal of Approval from the National Fibromyalgia Association, based in Orange, California, to gain distribution in major pharmacies in Canada and the United States including Rite-Aid, CVS/pharmacy and Shoppers Drug Mart. O24 Fibromyalgia is the first clinically tested, patented product available in national pharmacies that specifically targets the pain associated with Fibromyalgia. There are over 11 million North Americans who suffer from Fibromyalgia.
- The results of a randomized double blind clinical study on O24 Fibromyalgia for patients suffering from Fibromyalgia was published in the Practical Pain Management Journal, (January/February 2006 issue). This publication reaches over 37,000 medical professionals in the United States. 88 per cent of the patients who used O24 Fibromyalgia in the clinical study reported mild to markedly better improvement, versus only 7 per cent who used the placebo. A copy of the published study can be viewed at http://www.024zone.com/Clinicals.html.
- Swiss Medica announced a U.S. healthcare industry distribution deal with North American Physicians, Inc., ("NAPI") of Boca Raton, Florida. NAPI is distributing all three of Swiss Medica's products into the healthcare community including licensed dispensing physician offices, physician kiosks, pain management clinics, hospitals, therapy centers, hospital pharmacies, and chiropractor and podiatry clinics. The sampling and sale of products will be by healthcare professionals to patients in medical settings, experiencing either acute or chronic pain afflictions as well as mood instability.
OTHER MARKETING ACTIVITIES
- Swiss Medica attended several major, medical and biotech conferences in the United States and Canada as it continued to gain exposure and acceptance from the medical community for its unique patented, clinically tested OTC products. Swiss Medica continued to gain acceptance for its products as thousands of physicians in North America requested samples of Swiss Medica products for distribution to their patients.
- Swiss Medica continued its innovative consumer brand building program of aggressive consumer sampling, public relations and targeted media to build brand recognition of all three of its products in the United States and Canada.
Summary of Financial Results: (US$000)
Q1/2006 Q4/2005 Q1/2005
------- ------- -------
Revenues 1,222 2,145 1,127
EBITDA (1,063) (708) (620)
Net Loss (1,462) (1,254) (1,027)
Cash Used in Operations (399) (796) (2,784)
"We continue to be very optimistic about 2006 and beyond and expect significant growth as all three of our products gain momentum in the marketplace", continued Raghu Kilambi.
Swiss Medica defines EBITDA as earnings before interest and financing fees, taxes, depreciation, amortization, and other non-cash charges. Full second quarter results, for the period ending March 31, 2006, are included in the Company's 10-Q, which has been filed with the U.S. Securities and Exchange Commission.
Swiss Medica's management will host a conference call on Monday June 5th, 2006 at 4:00 pm EST to discuss the Company's first quarter highlights and go forward strategy. The details for dial-in and webcast will be forthcoming in a separate press release.
About Swiss Medica, Inc.
Swiss Medica is a specialty pharmaceutical company focused on commercializing over-the-counter clinically-tested, patented all-natural products that relieve chronic ailments. Swiss Medica builds its brands through innovative and focused distribution and marketing strategies. Swiss Medica's mission is to be a world leader in the commercialization of over-the-counter, safe and effective chronic ailment treatments. Please visit our websites at www.swissmedica.com, www.O24zone.com and www.pmsescape.com.
Swiss Medica's flagship product, the O24 Essential Oil Pain Neutralizer, holds US Patent #6,444,238B1. The O24 pain relief solution has been used and recommended for its fast-acting and long-lasting benefits by healthcare professionals and athletes in the United States, Canada and in Europe. O24 is widely available over-the-counter throughout the United States and Canada in leading pharmacies and other retailers. Customers can also visit www.O24zone.com, for ordering details and store locators for the nearest pharmacy.
Swiss Medica has recently launching the patented O24 Fibromyalgia pain reliever (US Patent #6,444,238B1) over-the-counter in North American retailers. The National Fibromyalgia Association (NFA) recently awarded O24 Fibromyalgia their first NFA Seal of Approval. Over 10 million Americans suffer from the long-term pain associated with Fibromyalgia. In a randomized double blind clinical trial conducted in 2005, 88 per cent of the patients who used O24 Fibromyalgia reported mild to markedly better improvement, versus only 7 per cent who used the placebo. Customers can also visit www.O24zone.com, for ordering details and store locators for the nearest retailer.
Swiss Medica also distributes PMS Escape® which holds US Patent #'s 5760014 and 5612320. PMS Escape® is a specially formulated group of carbohydrates, vitamins and minerals, clinically proven to reduce changes in mood and appetite that women experience during the premenstrual period. Customers can also visit: www.pmsescape.com for additional information and ordering details.
Forward-looking statements in this news release are made pursuant to the "Safe Harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including, without limitation, risks relating to acceptance of Swiss Medica's products in Canada, the United States and other countries, risks related to international sales and purchases and potential foreign currency exchange fluctuations, acceptance of Swiss Medica's products, increased levels of competition, dependence on intellectual property rights and other risks detailed from time to time in Swiss Medica's periodic reports filed with the United States Securities and Exchange Commission and other regulatory authorities.
Wednesday May 24, 8:00 am ET
TORONTO, ONTARIO--(MARKET WIRE)--May 24, 2006 -- Swiss Medica, Inc. (OTC BB:SWME.OB - News) today announced that TVA Productions of Studio City, California has started its major media campaign supporting Swiss Medica's O24 Fibromyalgia(TM) brand building across the United States. The "MediaBlitz" campaign to be conducted by TVA Productions is based on guaranteed to result in 41,000,000 estimated gross viewer impressions and will include:
- A 60-second commercial which will has begun airing on the DISH Network. The commercials will be running from May 11 to June 13, 2006. The DISH Network delivers programming to over 12 Million households, reaching 40 million viewers.
- In June 2006, TVA Productions will release a 60-second Radio News release professionally recorded and distributed in script form and on CD to 6,600 radio stations for use on regular news and talk shows, and a 60 second VFR (Video Feature Release) which will be distributed once a month on a 23-minute "Consumer Science News & Notes" Program (CSNN) to 1,000 TV stations, nationwide.
- In June 2006, A 2 minute segment will be featured on the national 1/2 hour TV newsmagazine, "Health & Home Report" for the month of June. HHR airs on 68 broadcast stations and more than 200 cable systems, reaching into 119 different markets. A copy of the 2 minute Swiss Medica segment on the HHR website at http://www.healthworldnews.tv/streaming … MedHHR.mov once the segments begins to air in June, and
- At least 30 days of in-flight entertainment on one major national airlines in the US.
"I have every expectation that our campaign for Swiss Medica will be one of our most successful to date," said TVA Productions President Jeffery Goddard. "The successful launch of Swiss Medica's O24 Fibromyalgia(TM) pain relief solution is a story that has all the right 'ingredients' for us to create compelling, newsworthy news features that are sure to generate a massive amount of positive exposure among the 20,000-plus media outlets which receive our news feeds."
" We are very confident in the ability of this campaign to reach a massive new audience for our products, the first three days of the campaign has already resulted in a 400% increase in activity on our website. This bodes well for Swiss Medica as the media blitz campaign ramps up." Said Grant Johnson President of Swiss Medica.
nun gilt es die 0.10 USD zu halten und die Konferenz sowie weitere News abzuwarten!
Wednesday May 31, 8:00 am ET
TORONTO, ONTARIO--(MARKET WIRE)--May 31, 2006 -- Swiss Medica, Inc. (OTC BB:SWME.OB - News) announced today that Emerging Markets Consulting, LLC has been retained to provide investor relations services for the Company.
Raghu Kilambi, CEO of Swiss Medica stated "I am excited to have Jim Painter and Emerging Markets Consulting join forces with Swiss Medica and share the unique story about our company and our revolutionary patented, clinically tested all natural chronic ailment products. The investment community needs to know more information about micro-cap companies that have real products, revenues and strong management teams. Swiss Medica is a growing company with tremendous potential and promise whose story needs to be in front of more investors."
James S. Painter, CEO of Emerging Markets Consulting stated, "We are thrilled to work with Swiss Medica and be able to get involved in marketing their company when their share price is so low. Our clients and the investment community are always looking for companies with strong and experienced management teams, viable business plans and products that have potential for huge growth. We believe the Swiss Medica story will be very well received by the investment community."
Swiss Medica's management will host a conference call on Monday, June 5, 2006 at 4:00 pm EST to discuss the Company's first quarter highlights and go forward strategy. Callers from the Toronto area are invited to dial 416 695-5259 at that time to participate. All other callers are invited to dial 1-877-888-4605 to participate. The conference will also be webcast with a direct link from www.swissmedica.com.
Please email questions you would like addressed during the conference call to djones@swissmedica.com.
About Emerging Markets Consulting, LLC
Emerging Markets Consulting, LLC specializes in bring little known companies to the attention of the financial community. EMC is actively focused on a carefully selected group of quality clients. EMC specializes in providing the highest level of professional service to only the most exciting companies on the market. Please visit us on the web to receive updates on our clients at http://emergingmarketsllc.com/index.htm
Swiss Medica, Inc. (OTCBB: SWME) announced today that the company has received Certificates of Free Sale from the US Food and Drug Administration ("FDA") for its patented O24 Pain Neutralizer and O24 Fibromyalgia products.
This issuance of these certificates by the FDA confirms that Swiss Medica's O24 Pain Neutralizer and O24(TM) Fibromyalgia products meet all the standards necessary for international export. Certificates of Free Sale confirm to foreign governments that the products meet or exceed all the standards necessary for them to be marketed in the United States, and meet specific US manufacturing regulations such as cGMP (current Good Manufacturing Practice). Many countries required these certificates prior to allowing importation of U.S. manufactured healthcare products like O24.
O24 Pain Neutralizer was launched nationally in the United States by Swiss Medica in 2005 and is available in the pain relief section of leading pharmacies throughout North America. The topical pain reliever and anti-inflammatory is a patented, medically/clinically tested, all natural product formulated with seven essential oils and no chemical binders. It has being used by and recommended by leading healthcare professionals including Medical Doctors and Doctors of Osteopathy. In addition, athletes from many sports including football, hockey, boxing and skiing like O24 for its quick pain relief and non-doping ingredients.
O24 Fibromyalgia was launched in late 2005 and is the first patented, clinically tested and non-prescription product specifically for patients to fight the intense, debilitating pain caused by Fibromyalgia. The product was awarded the first ever Seal of Approval from the U.S. National Fibromyalgia Association (NFA).
O24 has been medically and clinically tested and details of those trials are available at http://024zone.com/Clinicals.html.
Swiss Medica President and Chief Operating Officer Grant Johnson stated "The FDA's issuance of these certificates is coming at a perfect time. International interest in our products is growing quickly because of the science behind our products and the extraordinary efficacy of O24 for most people with pain."
Monday July 17, 8:00 am ET
TORONTO, ONTARIO--(MARKET WIRE)--Jul 17, 2006 -- Swiss Medica, Inc. (OTC BB:SWME.OB - News) announced today its intention to pursue military and international contracts with the appointment of Mr. Chad Christensen, Managing Director of Christensen Co., as Strategic Business Advisor.
ADVERTISEMENT
With a distinguished career in international banking, and advisor to several Fortune 500 companies, Mr. Christensen brings to Swiss Medica a wealth of national and international contacts at all levels of business and government. He will assist the Company in its continuing development of national and international markets.
Mr. Christensen is currently serving his second term in the Nevada State Legislature. He is also a Member of the Globalization Board, George Washington University's Elliott School of International Affairs; a Member of the Transportation & Homeland Security Committees, National Conference of State Legislatures (NCSL); a Member of the Commerce and Economic Development Committee, American Legislative Exchange Council (ALEC); and is an Honorary Commander at Nellis Air Force Base (Las Vegas, Nevada).
"With Mr. Christensen's extensive knowledge and experience in navigating government and international trade agreements, he will spearhead our efforts in these areas. Swiss Medica is pleased to have Mr. Christensen join our team and open up new business opportunities for our products." said Grant Johnson, Swiss Medica's President and COO.
Mr. Christensen is a graduate of Brigham Young University, and is Managing Director of Christensen Co., an agency specializing in business development and sales management.
Swiss Medica, Inc. (OTCBB: SWME) announced today that Fenco Automotive, a Canadian aftermarket automotive manufacturer with over 1,200 employees, has found that its factory workers are finding fast and effective pain relief using Swiss Medica's O24 Pain Neutralizer to manage their employees repetitive work strain and musculoskeletal disorders.
According to Marisa Cornacchia, R.N., the occupational health nurse for Fenco:
"With the introduction of O24 spray and wipes employees are now receiving effective pain control that helps them through their workday comfortably. O24 spray has been successfully treating the many different body areas of repetitive work strain and has been able to offer our workers an alternative to pain pills.
O24 has helped with our new program development to maximize worker health and keep our employees at work. Also the small wipe package are convenient for the employees to keep at the work station and apply it themselves, therefore encouraging self care for pain and minimizing visits to the nursing office. It has also been easier to maintain and restore the physical and psychosocial well being of our employees.
O24 has allowed our employees to maintain a comfort zone in their jobs by enabling them to manage their pain during their workday. This has been extremely beneficial in reducing absenteeism."
Grant Johnson, President and COO of Swiss Medica stated "it is our goal to have O24 used as the gold standard pain reliever within manufacturing environments where workers' safety and repetitive work strain and pain disorders are a growing concern. Medical Practitioners and consumers are telling us that they have safety concerns about oral pain relief products, especially in light of the recent study that appeared recently in the Journal of the American Medical Association. This clinical study raised concerns about people taking eight extra-strength acetaminophen tablets a day over a two week period. The study showed that 40% of the test subjects taking acetaminophen had abnormal test results that would signal liver damage, while the patients taking placebos over the same time showed no adverse liver test results".
TORONTO, Aug. 9, 2006 (PRIMEZONE) -- Swiss Medica, Inc. (OTCBB:SWME) announced today that the Sierra Mountain Minerals of Vancouver, British Columbia has incorporated Swiss Medica's patented O24 Pain Neutralizer into their new SierraSil(r) mineral formulation called "SierraSil Pain Relief Formula." This new topical private label product offers the safe, quick and effective pain relief of O24 and the arthritic healing attributes of SierraSil. SierraSil Pain Relief Formula will be available in nationwide in leading natural health retailers across Canada and the United States.
According to Grant Johnson, Swiss Medica's President and COO: "We are excited to be working with Sierra Mountain Minerals as we believe this new product offering will offer enhanced pain relief efficacy -- both short term and medium term. In addition, this new sales and distribution opportunity will enable us to expand our reach, open new markets and expand our clinical research regarding the amazing properties of both O24 Pain Neutralizer and SierraSil(r)."
According to Michael Bentley, EVP of Sierra Mountain Minerals: "We are pleased to be part of the Swiss Medica team. Over the last two years SierraSil has been added to a number of new and innovative products for joint health, pain relief and many more. Swiss Medica's extraordinary research, their patented formulas and excellent marketing team makes them a great partner for SierraSil. We look forward to a long and prosperous relationship."
About SierraSil
SierraSil is a distinct, naturally-occurring mineral composite found only in the high Sierra Mountains. SierraSil has been clinically shown to protect cartilage from breakdown and daily wear and tear by up to 73 percent and, unlike other nutraceuticals, suppresses gene expression associated with inflammatory responses.
About Sierra Mountain Minerals, Inc.
Was founded in 2003 by Peter and Michael Bentley to provide its proprietary new mineral supplement SierraSil(r) to those needing fast-acting, powerful joint and cartilage support, Sierra Mountain Minerals has experienced rapid growth in North America. Their products are available throughout the US and Canada and fine health food stores. Peter Bentley is the President of Sierra Mountain Minerals and is the Chairman of the Board of Canfor Corporation, a CDN3.7 billion revenue publicly traded forestry product company (CFP on the Toronto Stock Exchange) and also served for many years as a director of Bank of Montreal and Shell Canada Ltd. Michael Bentley, the Company's Chief Operations Officer, has held a variety of management positions at a leading forest products company. He has a Master of Science in Management from Stanford. He is also a member of the Institute of Corporate Directors and serves on a variety of business and not-for-profit boards.
TORONTO, Aug. 23, 2006 (PRIMEZONE) -- Swiss Medica, Inc. (OTCBB: SWME) announced today that the Caribbean Institute of Orthopedics ("CIO") has become a Swiss Medica international distribution partner. CIO, with offices in Santo Domingo, Dominican Republican will be marketing and distributing Swiss Medica's O24 products throughout the Caribbean.
According to Kamille Ramsunder, the President of the Caribbean Institute of Orthopedics:
"We are officially endorsing Swiss Medica's award winning O24 Pain Neutralizer as our flagship pain product for this region. CIO is hoping to fight crippling diseases like Osteoarthritis/Rheumatoid Arthritis and Fibromyalgia in the most natural way and we have found that there is no better way to relieve chronic pain than to use Swiss Medica's O24 Pain Neutralizer. Swiss Medica's O24 Pain Neutralizer has also been endorsed by our partners, The Canadian Institute of Orthopedics."
Grant Johnson, President and COO of Swiss Medica stated, "We are proud to see the international orthopedic community reach out and endorse our products, and it is our goal to continue to grow Swiss Medica's international presence through these strategic distribution deals. We expect to make several more announcements regarding our international expansion plans over the next several months."
About the Caribbean Institute of Orthopedics
The Caribbean Institute of Orthopedics (CIO) supplies professional services to patients requiring orthotic devices and specialized braces for a variety of biomechanical problems for the entire Caribbean region. The Caribbean region compromises the islands of Bahamas, Barbados, Dominican Republic, Cuba, and Aruba, among others, and according to the latest United Nations survey (2004) of the Caribbean, the twenty-four island nations have a population over 38-million and a Gross Domestic Product that is growing at 2.4% a year.
TORONTO, Aug. 24, 2006 (PRIMEZONE) -- Swiss Medica, Inc. (OTCBB:SWME) announced today that Golf Magazine has distributed over 400,000 O24 Pain Neutralizer information postcards with an attached free sample towelette as an insert to their 55+ year old magazine subscribers in the United States. The sample towelettes were included in the September 2006 issue of Golf Magazine. Golf Magazine is the world's most widely read golf publication, and is read by millions of golfers each month.
Grant Johnson, President and COO of Swiss Medica stated that "While the magazine has only been in circulation for less than a week, we are already seeing a dramatic pick-up on our www.024zone.com website and 1-877 toll-free customer care line regarding where they can buy O24."
O24 is also being sampled to over 100,000 golfers this summer at golf tournaments in Canada and in clubhouses including Angus Glen Golf Club (north of Toronto), the home to the 2007 Canadian Open PGA golf tournament.
"O24 has received an enthusiastic response from golfers who have found its strong and quick pain relief to be very effective to deal with pain and stiffness, both on and off on the Golf Course," stated Kevin Thistle, Vice President/General Manager of Angus Glen Golf Club.
Die kostenlose Print- oder PDF-Version jetzt über info@dellarue.de vorbestellen.
(Bei der Printversion bittet DEL LA RUE die Versandadresse mit anzugeben.)
Die funds & finance ist deutschlandweit die erste und einzige Messe, auf der alle wichtigen Marktteilnehmer der Fonds Community zusammenfinden. Neben dem Austausch mit Premium Ausstellern aus den Bereichen offener, geschlossener und alternativer Fonds, Verbänden, Fachmedien und weiteren relevanten Marktteilnehmern der Finanzbranche bietet Ihnen die funds & finance 2006 ein umfangreiches Vortragsprogramm und Podiumsdiskussionen mit Fachvorträgen renommierter Referenten aus der Finanzbranche, Medien, Verbänden und Politik.
Die Freikarten gelten für beide Messetage und umfassen ein exklusives Catering.
- Wert der Karten 45,- EURO.
- Einsendeschluss an info@dellarue.de ist Fr. der 08. September um 24.00 Uhr.
Mehr informationen auf http://www.dellarue.de
Wir vergeben Freikarten für die funds & finance Messe am 12. und 13. September in Köln.
Die funds & finance ist deutschlandweit die erste und einzige Messe, auf der alle wichtigen Marktteilnehmer der Fonds Community zusammenfinden. Neben dem Austausch mit Premium Ausstellern aus den Bereichen offener, geschlossener und alternativer Fonds, Verbänden, Fachmedien und weiteren relevanten Marktteilnehmern der Finanzbranche bietet Ihnen die funds & finance 2006 ein umfangreiches Vortragsprogramm und Podiumsdiskussionen mit Fachvorträgen renommierter Referenten aus der Finanzbranche, Medien, Verbänden und Politik.
- 2-Tageskarte (12. und 13. Sep.)
- inkl. 50% Rabbat auf das exklusive catering
- Wert einer Karte: 45,- EURO.
- Einsendeschluss an info@dellarue.de ist Mo. der 11. September um 13.00 Uhr.
- Die Messe ist ausschließlich für Finanzintermediäre, nicht für Privatbesucher.
Bedenken Sie bitte, die Karten können erst am 12. Sept. bei Ihnen eintreffen.
TORONTO, Sept. 11, 2006 (PRIMEZONE) -- Swiss Medica, Inc. (OTCBB:SWME) is pleased to announce that Swiss Medica GmbH, a German privately held company, has fulfilled all legal obligations under the laws of Germany and has been approved to raise up to 10 million Euros in gross proceeds via a prospectus offering. These funds will be used to invest into non-convertible preferred shares of Swiss Medica, Inc. at a price of 1.25 euro per preferred share.
The preferred shares are not convertible into publicly traded common shares of Swiss Medica, Inc. and will have a dividend yield of 16 percent. The preferred shares cannot be redeemed prior to December 31, 2008 and mature on December 31, 2011.
Information on Swiss Medica GmbH is only available in German at http://www.swissmedica.de/
Raghu Kilambi, Swiss Medica's CEO, noted, "While this regulatory approval took longer than expected, we feel that the structure of this proposed financing provides much long-term flexibility for Swiss Medica Inc. as it grows its North American and international businesses. Swiss Medica Inc. plans to use proceeds of this financing to fund its growth including working capital investment, sales/marketing and debt reduction."
German individual and institutional investors are expected to invest in this financing, which will have multiple closings over the next several months.
The subject of the German regulatory approval by the BaFin is only that the offer includes formally all information required under the laws of Germany for this kind of offering but not that the contents of the offering are true or that the contents have been controlled by BaFin.
The information contained herein does not constitute or form part of an offer or solicitation of an offer to purchase or subscribe for securities for sale in the United States and Canada. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933, as amended and may not be offered or sold in the United States unless registered or pursuant to an exemption from such registration. No public offering of securities is being made in the United States.
TORONTO, Sept. 14, 2006 (PRIMEZONE) -- Swiss Medica, Inc. (OTCBB:SWME) announced today that Heritage Healthcare of the Republic of South Africa has become Swiss Medica's latest international distribution partner. Heritage Healthcare will be marketing and distributing Swiss Medica's O24 products throughout South Africa ("SA").
Heritage Healthcare will be commencing a national marketing campaign which will include promoting 024 into the major pharmacy chains and distributors and sampling the 024 products to orthopedic surgeons, physiotherapists and pain management specialists in South Africa.
According to Gary Schach, Founder of Heritage Healthcare:
"South Africans are sports crazy and many suffer from pain caused by over-doing activities whilst participating in soccer, rugby, athletics, tennis, running and golf. I personally have 26 years experience in developing, manufacturing and marketing healthcare and surgical products to the SA market and feel certain that 024 will soon become a leading contender in the natural product pain relief sector in South Africa."
Grant Johnson, President and COO of Swiss Medica, stated, "We are proud to see the international healthcare community recognize and support the strengths of our brands: all-natural, clinically-tested products that provide fast, safe and effective relief. It is our goal to continue to grow Swiss Medica's international presence through these strategic distribution deals. We expect to make several more announcements regarding our international expansion plans over the next several months."
About the Heritage Health
Heritage Healthcare is a division of Heritage Surgical Products cc of South Africa who is an innovative leader in the manufacture and supplier of unique, high quality urological, incontinence, surgical and medical products servicing the South African marketplace. Heritage Healthcare has a strong and respected relationship with many healthcare professionals, pharmacists and allied professionals throughout South Africa. The Republic of South Africa has a population of 42.4 million, a Gross Domestic Product in 2005 of $570 Billion (18th highest Worldwide) and a per capita income of $12,160 (54th highest in the world).
Quelle:http://www.dellarue.de
TORONTO, Sept. 19, 2006 (PRIMEZONE) -- Swiss Medica, Inc. (OTCBB:SWME) is pleased to announced that it has been ranked No. 3 in the top 50 emerging growth companies in Canada according to the 7th annual PROFIT HOT 50 ranking. The PROFIT HOT 50 is the definitive ranking of Canada's emerging growth companies and is published in the October 2006 issue of "PROFIT: Your Guide to Business Success" and online at www.PROFITguide.com. The PROFIT HOT 50 ranks young firms by two-year revenue growth.
According to Ian Portsmouth, editor of PROFIT, "The PROFIT HOT 50 companies represent the ambition, sophistication and immense contribution of Canada's entrepreneurial sector. PROFIT is proud to celebrate the success of these businesses and to share their growth strategies."
"I am extremely grateful to our employees, customers, shareholders and other stakeholders who have supported our vision of commercializing elite over-the-counter, patented all natural products for chronic ailments. We believe that we are still very early in the product acceptance cycle for science-based over-the-counter products for chronic ailments and increasing concerns about side effects from prescription drugs will allow Swiss Medica's patented products to continue to gain significantly more acceptance from consumers and the medical community in North America and throughout the world," said Raghu Kilambi, CEO of Swiss Medica Inc.
About PROFIT: Your Guide to Business Success
PROFIT: Your Guide to Business Success, offers news, strategies, tips, interviews and other recourses to the CEOs of Canadian growth companies. Each year, PROFIT, which currently reaches more than 370,000 readers nationally, hosts a number of events that bring together business leaders in the fast-growth segments and champions the interests of those leaders. PROFIT was founded in April 1982 as Canada's first national magazine geared to entrepreneurs. Visit PROFITguide.com.
Voraussichtlich dürfte das durchgehen, in einem Verhältnis von bis zu 1 : 10!
Vor drei Wochen haben wir unseren DEL LA RUE - Investment Report über die Swiss Medica Inc. veröffentlicht. Seither hat sich einiges getan. Es gab zwar keine nennenswerten Kurssprünge, aber eine Vielzahl von fundamentalen Neuigkeiten.
Das Unternehmen erschloss mit der Karibik und Süd Afrika erstmals internationale Absatzmärkte. Auch auf dem nordamerikanischen Markt schaffte es die swissmedica Inc. in den letzten Wochen auf PMS Escape aufmerksam zu machen und konnte neue Kunden gewinnen, nennenswert vor allem Rite Aid und Big Y Food, hinzu kamen auch mehrere kleine Supermarktketten.
Unsere Prognosen, die Expansion voranzutreiben und verstärkt auf die Produkte aufmerksam zu machen, scheinen einzutreten. Einzig allein die Umsätze im Geschäftsjahr 2006 entsprachen bisher nicht unseren Erwartungen. So konnten die erhofften Zuwächse von 10 bis 20 % nicht erzielt werden, sondern es kam zu einem Einbruch von bis zu 50%, zurückzuführen auf die Rückgabe von Warensendungen zweier amerikanischer Großkunden. So stellte Walgreens den Verkauf der 024 Produkte ein und CVS den Verkauf von PMS Escape über die Geschäftsfilialen.
Raghu Kilambi war über diese Entwicklung sehr enttäuscht, hält aber weiter am Unternehmenserfolg und den Produkten fest. So kaufte er am Tag nach der Veröffentlichung der letzten Quartalsergebnisse 100.000 Aktien als symbolisches Zeichen.
Das Unternehmen stellt seine Weichen, so wurde am 4. September bekannt, dass die BaFin den Verkaufsprospekt der swissmedica Beteiligungs GmbH über Genussrechtskapital an der swissmedica Inc. genehmigte. Auf der anschließende Investorenmesse am 12. und 13. September in Köln konnte sich das Unternehmen erstmals deutschen Investoren präsentieren und Geschäftskontakte knüpfen.
Auch wir sehen in der Unternehmensbeteiligung an der swissmedica Inc. über Genussrechtskapital eine attraktive Alternative zur Aktienanlage. Zudem erhält die swissmedica Inc. dadurch die für Wareneinkäufe und Marketingkampagnen nötigen finanziellen Mittel.
Den Investment Report über die swissmedica Inc. erhalten Sie online unter www.dellarue.de/Report.html
Haben Sie Interesse am Verkaufsprospekt über die Genussrechtsbeteiligung an der swissmedica Inc., mit einer Verzinsung von 9,5% p.a. auf einer Laufzeit von mindestens 2 und maximal 5 Jahre, wenden Sie sich bitte an info@dellarue.de, wir schicken Ihnen dann umgehend den Prospket per Hauspost zu.
Weitere Informationen über das DEL LA RUE – Investment Team und unsere Investmentideen finden Sie unter www.dellarue.de.
(21.09.06) Swiss Medica wird voraussichtlich ein Reverse Stock Split in einem Verhältnis von bis zu 1 : 10 durchführen.
(21.09.06) Hillers Supermarket aus Michigan (6 Filialen) führt demnächst PMS Escape ein.
(19.09.06) Swiss Medica landet auf Platz 3. der besten kanadischen Newcomer-Firmen.
(19.09.06) Laut inernen Informationen wird Yokes Foods (13 Filialen) innerhalb der nächsten Wochen, PMS Escape einführen.
(14.09.06) Swiss Medica Inc. verkündet Absatzvertrag mit Heritage Healthcare für Südafrika.
(12.09.06) Die Supermarktkette "Big Y" (53 Filialen) wird laut internen Informationen demnächst PMS Escape einführen.
(11.09.06) Presseberich der Swiss Medica Inc. über die Zulassung des Verkaufsprospekts.
(05.09.06) Der Prospekt für die Genussrechte der swissmedica Beteiligungs- GmbH wurde genehmigt.
(03.09.06) Die swissmedica Inc. ist am 12. und 13. September auf der funds & finance Messe in Köln.
Quelle: www.dellarue.de/Insider.html